糖皮质激素在治疗儿童重症肺炎支原体肺炎(MPP)中的价值  

The value of glucocorticoid in the therapy of children severe Mycoplasma pneumoniae pneumonia(MPP)

作　　者：丁圣刚[1] 王建[1] 王亚亭[1] 丁俊丽[1] 

机构地区：[1]安徽医科大学第一附属医院儿科,合肥230022

出　　处：《复旦学报（医学版）》2012年第2期180-183,共4页Fudan University Journal of Medical Sciences

摘　　要：目的探讨糖皮质激素在儿童重症肺炎支原体肺炎治疗中的作用。方法采用明胶颗粒凝聚法检测血MP-IgM,对MP-IgM≥1∶80且符合重症肺炎支原体肺炎临床诊断标准的53例患儿,依据是否使用糖皮质激素分成治疗组35例、对照组18例,比较两组之间临床症状、住院时间和并发症差异。结果治疗组35例患儿临床症状消失快、住院时间缩短、并发症少。结论糖皮质激素可明显抑制重症肺炎支原体肺炎炎症反应,减轻由此对机体的损害,改善预后。Objective To probe the therapeutic effects of glucocorticoids on severe Mycoplasma pneumoniae pneumonia （MPP）. Methods Serum IgM titers for M. pneumoniae （MP） were determined by the gelatin particles condensed method. Fifty-three children whose serum MP-IgM≥ 1：80 were recruited into our study. All subjects met the clinical diagnosis standards for severe MPP, and were divided into glucocorticoid treatment group （35cases） and control group （18 cases）. The clinical symptoms, hospitalization time and complications were documented. Results Compared with the control group, clinical symptoms of treatment group disappeared more quickly, accompanied with shorter hospitalization and less complications. Conclusions Glucocorticoid can significantly inhibit the inflammatory response of severe MPP, alleviate the damage to the body by mycoplasma pneumoniae infection and improve the prognosis of severe MPP.

关 键 词：肺炎支原体肺炎(MPP) 重症 儿童 糖皮质激素 

分 类 号：R725.6[医药卫生—儿科]